Menu Search
Equities

Max Healthcare Institute Ltd

MAXHEALTH:NSI

Max Healthcare Institute Ltd

Actions
Health CareHealth Care Providers
  • Price (INR)999.95
  • Today's Change13.95 / 1.41%
  • Shares traded1.90m
  • 1 Year change+62.46%
  • Beta0.7477
Data delayed at least 15 minutes, as of Nov 22 2024 10:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform6
Hold3
Sell4
Strong Sell0

Share price forecast in INR

The 18 analysts offering 12 month price targets for Max Healthcare Institute Ltd have a median target of 1,140.00, with a high estimate of 1,250.00 and a low estimate of 615.00. The median estimate represents a 15.62% increase from the last price of 986.00.
High26.8%1,250.00
Med15.6%1,140.00
Low-37.6%615.00

Dividends in INR

In 2024, Max Healthcare Institute Ltd reported a dividend of 1.50 INR, which represents a 50.00% increase over last year. The 11 analysts covering the company expect dividends of 1.18 INR for the upcoming fiscal year, a decrease of 21.07%.
Div growth (TTM)50.00%
More ▼

Earnings history & estimates in INR

On Nov 05, 2024, Max Healthcare Institute Ltd reported 2nd quarter 2025 earnings of 2.88 per share.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+1.06%
Max Healthcare Institute Ltd reported annual 2024 earnings of 10.84 per share on May 22, 2024.
Average growth rate+181.72%
More ▼

Revenue history & estimates in INR

Max India Limited had 2nd quarter 2025 revenues of 17.07bn. This missed the 20.52bn consensus estimate of the 10 analysts following the company. This was 32.88% above the prior year's 2nd quarter results.
Average growth rate+5.90%
Max India Limited had revenues for the full year 2024 of 54.06bn. This was 18.49% above the prior year's results.
Average growth rate+30.50%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.